http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2021, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 30 Jun 2021 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Comments+on+Orphazyme%E2%80%99s+Promising+24-Month+Interim+Trial+Results+of+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18624741.html Wed, 30 Jun 2021 08:00:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html for the full story. http://www.streetinsider.com/Business+Wire/CytRx+Notes+Orphazyme%E2%80%99s+Regulatory+Update+from+the+FDA+on+Arimoclomol+for+Niemann-Pick+Disease+Type+C/18578308.html Fri, 18 Jun 2021 16:30:00 -0400 A.06822034 CYTR ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Thu, 13 May 2021 08:00:00 -0400 A.42613792 CYTR IBRX ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Thu, 13 May 2021 08:00:00 -0400 A.42613792 CYTR IBRX ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Thu, 13 May 2021 08:00:00 -0400 A.42613792 CYTR IBRX ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Thu, 13 May 2021 08:00:00 -0400 A.42613792 CYTR IBRX ORPH ORPHA ORPHA.CO http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html for the full story. http://www.streetinsider.com/Press+Releases/CytRx+Comments+on+Quarterly+Results+and+Year-to-Date+Progress/18412943.html Thu, 13 May 2021 08:00:00 -0400 A.42613792 CYTR IBRX ORPH ORPHA ORPHA.CO